@article{3054627,
    title = "Hemostatic effects of SF6 after diabetic vitrectomy for vitreous
hemorrhage",
    author = "Koutsandrea, CN and Apostolopoulos, MN and Chatzoulis, DZ and Parikakis, and EA and Theodossiadis, GP",
    journal = "Acta Ophthalmologica Scandinavica",
    year = "2001",
    volume = "79",
    number = "1",
    pages = "34-38",
    publisher = "Wiley",
    issn = "1395-3907, 1600-0420",
    doi = "10.1034/j.1600-0420.2001.079001034.x",
    keywords = "diabetic retinopathy; vitrectomy; vitreous hemorrhage recurrence",
    abstract = "Purpose: To investigate the hemostatic effects of SF6 gas in preventing
post-operative vitreous hemorrhage in diabetic vitrectomy,
Methods: A prospective, randomized study of 33 diabetic eyes with
vitreous hemorrhage, treated by vitrectomy, In 17 of our cases SF6 20%
was injected into the eye at the end of the operation, while in 16 cases
BSS remained in the vitreous cavity,
Results: The incidence of vitreous hemorrhage recurrence was 17.6% for
the SF6 group and 12.5% for the BSS group (statistically not
significant). Progression of lens opacities was observed in 23.5% of
the SF6 group, and in 18.8% of the BSS group (statistically not
significant, with a higher incidence in the SF6 group).
Conclusions: SF6 gas did not show hemostatic effects in the cases
studied. Furthermore, it may have contributed to cataract progression.
Therefore we suggest that the use of SF6 is not recommended as a
treatment modality in preventing new vitreous hemorrhage after diabetic
vitrectomy."
}